{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:33:55Z","timestamp":1791232435089,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,10,6]],"date-time":"2012-10-06T00:00:00Z","timestamp":1349481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,10,6]],"date-time":"2012-10-06T00:00:00Z","timestamp":1349481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s10637-012-9885-8","type":"journal-article","created":{"date-parts":[[2012,10,5]],"date-time":"2012-10-05T03:22:59Z","timestamp":1349407379000},"page":"751-759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors"],"prefix":"10.1007","volume":"31","author":[{"given":"Maja J. A.","family":"de Jonge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hamberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawna","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Benjamin","family":"Suttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Hodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thangam","family":"Arumugham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lini N.","family":"Pandite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert I.","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,6]]},"reference":[{"key":"9885_CR1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2002.37263","volume":"29","author":"J Folkman","year":"2002","unstructured":"Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15\u201318","journal-title":"Semin Oncol"},{"key":"9885_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1101\/gad.1756509","volume":"23","author":"RG Jones","year":"2009","unstructured":"Jones RG, Thompson CB (2009) Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 23:537\u2013548","journal-title":"Genes Dev"},{"key":"9885_CR3","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669\u2013676","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"9885_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1634\/theoncologist.5-suppl_1-37","volume":"5","author":"G Gasparini","year":"2000","unstructured":"Gasparini G (2000) Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5(Suppl 1):37\u201344","journal-title":"Oncologist"},{"key":"9885_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A","volume":"80","author":"PJ Paley","year":"1997","unstructured":"Paley PJ, Staskus KA, Gebhard K et al (1997) Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80:98\u2013106","journal-title":"Cancer"},{"key":"9885_CR6","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1128\/MCB.21.12.3995-4004.2001","volume":"21","author":"E Laughner","year":"2001","unstructured":"Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995\u20134004","journal-title":"Mol Cell Biol"},{"key":"9885_CR7","doi-asserted-by":"publisher","first-page":"22473","DOI":"10.1074\/jbc.M500963200","volume":"280","author":"RJ Phillips","year":"2005","unstructured":"Phillips RJ, Mestas J, Gharaee-Kermani M et al (2005) Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase\/PTEN\/AKT\/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 280:22473\u201322481","journal-title":"J Biol Chem"},{"key":"9885_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/416279b","volume":"416","author":"Y Izumi","year":"2002","unstructured":"Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK (2002) Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416:279\u2013280","journal-title":"Nature"},{"key":"9885_CR9","first-page":"257","volume":"5","author":"P Perrotte","year":"1999","unstructured":"Perrotte P, Matsumoto T, Inoue K et al (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5:257\u2013265","journal-title":"Clin Cancer Res"},{"key":"9885_CR10","first-page":"1523","volume":"151","author":"AM Petit","year":"1997","unstructured":"Petit AM, Rak J, Hung MC et al (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2\/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523\u20131530","journal-title":"Am J Pathol"},{"key":"9885_CR11","first-page":"5090","volume":"61","author":"A Viloria-Petit","year":"2001","unstructured":"Viloria-Petit A, Crombet T, Jothy S et al (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61:5090\u20135101","journal-title":"Cancer Res"},{"key":"9885_CR12","unstructured":"VOTRIENT (pazopanib) tablets [prescribing information]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022465s002lbl.pdf. Accessed June 8, 2012"},{"key":"9885_CR13","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1200\/JCO.2007.14.0590","volume":"26","author":"HL Gomez","year":"2008","unstructured":"Gomez HL, Doval DC, Chavez MA et al (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26:2999\u20133005","journal-title":"J Clin Oncol"},{"key":"9885_CR14","unstructured":"TYKERB (lapatinib) tablets [prescribing information]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022059s007lbl.pdf. Accessed June 6, 2012"},{"key":"9885_CR15","unstructured":"GlaxoSmithKline Study of safety and tolerability of GW786034 given with lapatinib in cancer patients. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00158782?term=lapatinib%2C+pazopanib%2C+phase+i&rank=4. Accessed June 20, 2012"},{"key":"9885_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/clpt.2010.158","volume":"88","author":"BC Goh","year":"2010","unstructured":"Goh BC, Reddy NJ, Dandamudi UB et al (2010) An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther 88:652\u2013659","journal-title":"Clin Pharmacol Ther"},{"key":"9885_CR17","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","volume":"35","author":"NP van Erp","year":"2009","unstructured":"van Erp NP, Gelderblom H, Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35:692\u2013706","journal-title":"Cancer Treat Rev"},{"key":"9885_CR18","unstructured":"National Cancer Institute (2006) Common terminology criteria for adverse events v3.0 (CTCAE). http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed June 8, 2012"},{"key":"9885_CR19","unstructured":"European Organization for Research and Treatment of Cancer, National Cancer Institute, National Cancer Institute of Canada Clinical Trials Group Response Evaluation Criteria In Solid Tumors, Version 1.1 (published 2009). http:\/\/www.recist.com\/. Accessed June 8, 2012"},{"key":"9885_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/rcm.1327","volume":"18","author":"S Hsieh","year":"2004","unstructured":"Hsieh S, Tobien T, Koch K, Dunn J (2004) Increasing throughput of parallel on-line extraction liquid chromatography\/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development. Rapid Commun Mass Spectrom 18:285\u2013292","journal-title":"Rapid Commun Mass Spectrom"},{"key":"9885_CR21","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","volume":"28","author":"KL Blackwell","year":"2010","unstructured":"Blackwell KL, Burstein HJ, Storniolo AM et al (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124\u20131130","journal-title":"J Clin Oncol"},{"key":"9885_CR22","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1158\/1535-7163.MCT-10-0197","volume":"9","author":"J Perry","year":"2010","unstructured":"Perry J, Ghazaly E, Kitromilidou C, McGrowder EH, Joel S, Powles T (2010) A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP. Mol Cancer Ther 9:3322\u20133329","journal-title":"Mol Cancer Ther"},{"key":"9885_CR23","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1124\/mol.65.6.1485","volume":"65","author":"C Ozvegy-Laczka","year":"2004","unstructured":"Ozvegy-Laczka C, Hegedus T, Varady G et al (2004) High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65:1485\u20131495","journal-title":"Mol Pharmacol"},{"key":"9885_CR24","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","volume":"158","author":"C Hegedus","year":"2009","unstructured":"Hegedus C, Ozvegy-Laczka C, Apati A et al (2009) Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 158:1153\u20131164","journal-title":"Br J Pharmacol"},{"key":"9885_CR25","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/sj.bjc.6603985","volume":"97","author":"Y Mi","year":"2007","unstructured":"Mi Y, Lou L (2007) ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. Br J Cancer 97:934\u2013940","journal-title":"Br J Cancer"},{"key":"9885_CR26","doi-asserted-by":"publisher","first-page":"e5172","DOI":"10.1371\/journal.pone.0005172","volume":"4","author":"LS Zheng","year":"2009","unstructured":"Zheng LS, Wang F, Li YH et al (2009) Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One 4:e5172","journal-title":"PLoS One"},{"key":"9885_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2007.07.034","volume":"44","author":"CM Booth","year":"2008","unstructured":"Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA (2008) Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer 44:19\u201324","journal-title":"Eur J Cancer"},{"key":"9885_CR28","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/JCO.2009.26.9571","volume":"28","author":"BJ Monk","year":"2010","unstructured":"Monk BJ, Mas Lopez L, Zarba JJ et al (2010) Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 28:3562\u20133569","journal-title":"J Clin Oncol"},{"issue":"suppl;15s","key":"9885_CR29","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1200\/jco.2008.26.15_suppl.1016","volume":"26","author":"D Slamon","year":"2008","unstructured":"Slamon D, Gomez HL, Kabbinavar FF et al. (2008) Randomized study of pazopanib\u2009+\u2009lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J Clin Oncol 26(suppl;15s):abstr 1016","journal-title":"J Clin Oncol"},{"key":"9885_CR30","doi-asserted-by":"crossref","unstructured":"Slamon D, Stemmer SM, Johnston S et al. (2008) Phase 2 study of dual VEGF\/HER2 blockade with pazopanib\u2009+\u2009lapatinib in patients with first-line HER2-positive advanced or metastatic breast cancer. Presented at the 31st Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 10\u201314, Abstract 4114","DOI":"10.1158\/0008-5472.SABCS-4114"},{"key":"9885_CR31","unstructured":"GlaxoSmithKline Pazopanib plus lapatinib compared to lapatinib alone in subjects with advanced or metastatic breast cancer. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00347919?term=00347919&rank=1. Accessed July 2, 2012"},{"key":"9885_CR32","unstructured":"GlaxoSmithKline Pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma (VEG102857). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00350727?term=00350727&rank=1. Accessed July 2, 2012"},{"key":"9885_CR33","unstructured":"GlaxoSmithKline Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00430781?term=00430781&rank=1. Accessed July 2, 2012"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9885-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-012-9885-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9885-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9885-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:44:46Z","timestamp":1678560286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-012-9885-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,6]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["9885"],"URL":"https:\/\/doi.org\/10.1007\/s10637-012-9885-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,6]]},"assertion":[{"value":"14 August 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}